Introduction: Matrix Gla protein (MGP) is a central calcification inhibitor of vascular wall. The biological activation of the calcification-inhibitory protein MGP can be achieved by simple administration of oral vitamin K.
Aim: The study was conducted to assess the effect of vitamin k supplementation on vascular calcification and to evaluate its effect on MGA in hemodialysis patients.
Materials and Methods: Forty adult patients with end stage renal disease (ESRD) on regular hemodialysis sessions, thrice weekly, were enrolled in the study and were randomly assigned into two groups. Vitamin K group consisted of 20 patients were given oral vitamin K at 10 mg after each session of dialysis for a duration of one year. No-Vitamin K group included 20 patients didn’t receive vitamin K. All patients were subjected to the following: Matrix Gla protein (MGP), in addition to, plain digital abdominal x-ray and doppler ultrasound.
Results: After one-year of vitamin K supplementation, a significant increase in MGP levels in Vitamin K group (75.7±26 ng/mL) were noticed. There were no significant changes in CIMT and AACS in Vitamin K group after vitamin K supplementation in compared to their baseline levels, while the CIMT and AACS were significantly increased in No-Vitamin K group in compared to their baseline levels.
Conclusion: Vitamin K supplementation could not stop vascular calcifications but significantly attenuate their progression.
London G, Guerin A, Marchais S et al (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. NDT 18(9):1731–1740.
Noels, H.; Boor, P.; Goettsch, C.; Hohl, M.; Jahnen-Dechent, W.; Jankowski, V.; Kindermann, I.; Kramann, R.; Lehrke, M.; Linz, D.; et al. The new SFB/TRR219 Research Centre. Eur. Heart J. 2018, 39, 975–977.
Kristen L. Jablonski, Ph.D. and Michel Chonchol: Vascular Calcification in End-Stage Renal Disease. Hemodial Int. 2013 Oct; 17(0 1): 10.1111/hdi.12084.
Mizobuchi M, Towler D, Slatopolsky E: Vascular calcification: the killer of patients with chronic kidney disease. Journal of the American Society of Nephrology: JASN. 2009; 20:1453–1464.
Shroff R, Long DA, Shanahan C: Mechanistic insights into vascular calcification in CKD. Journal of the American Society of Nephrology: JASN. 2013; 24:179–189.
Schurgers, Barreto, Barreto, et al: The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol. 2010; 5:568-575.
Holden, Hopman, Zimmerman, et al: Warfarin and aortic valve calcification in hemodialysis patients. J. Nephrol. 2007, 20, 417–422.
Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994; 93:2393–402.
Tintut Y, Parhami F, Bostrom K, Jackson SM, Demer LL: cAMP stimulates osteoblast-like differentiation of calcifying vascular cells. Potential signaling pathway for vascular calcification. J Biol Chem. 1998; 273:7547–53.
Canfield AE, Doherty MJ, Kelly V, Newman B, et al: Matrix Gla protein is differentially expressed during the deposition of a calcified matrix by vascular pericytes. FEBS Lett. 2000; 487:267–71.
Luo G, Ducy P, McKee MD, Pinero GJ, et al: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997; 386:78–81.
Yao Y, Bennett BJ, Wang X, Rosenfeld ME, et al: Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res. 2010; 107:485–94.
Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, et al: Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost. 2007; 5:2503–11.
Price PA, June HH, Buckley JR, Williamson MK: Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21:1610–6.
Garred LJ, Barichello DL, DiGiuseppe B, McCready WG,et al: Simple Kt/V formulas based on urea mass balance theory. ASAIO J 1994; 40:997–1004.
Silaghi CN, Fodor D, Crăciun AM et al. Circulating matrix Gla protein: a potential tool to identify minor carotid stenosis with calcification in a risk population. Clin Chem Lab Med 2013; 51(5):1115-23.
Schousboe JT, Wilson KE, Hangartner TN. Detection of aortic calcification during vertebral fracture assessment (VFA) compared to digital radiography. Plos One. 2007; 2: e715-e9.
Schurgers LJ, Teunissen KJ, Knapen MH, Kwaijtaal M, vanest R, et al: Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: Undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005; 25: 1629–1633.
Churgers LJ, Barreto DV, Barreto FC, Liabeuf S, et al: The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report. Clin J Am Soc Nephrol 2010; 5: 568–575.
Schlieper G, Westenfeld R, Krüger T et al: Circulating Nonphosphorylated Carboxylated Matrix Gla Protein Predicts Survival in ESRD. JASN February 1, 2011; 22: 2 387-395.
Rennenberg RJ, Schurgers LJ, Vermeer C, Scholte JB et al: Renal handling of matrix Gla-protein in humans with moderate to severe hypertension. Hypertens Res 2008; 31: 1745–1751.
Schlieper, Aretz, Verberckmoes, et al: Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol. 2011; 21: 689-696.
Hayashi M, Takamatsu I, Kanno Y, et al: A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012; 27: 1580-1584.
Cranenburg EC, Koos R, Schurgers LJ, et al: Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost. 2010; 104: 811-822.
Caluwe R, Vandecasteele S, Van Vlem B, et al: Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant. 2014; 29: 1385-1390.
Beulens, J. W. Bots, M. L. Atsma, F. et al: High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis 2009. Apr; 203 (2): 489-93.
Ketteler M, Bongartz P, Westenfeld R et al: Association of low fetuin A (AHSG) concentrations in serum with cardiovascular mortality in pa¬tients on dialysis: a cross-sectional study. Lancet 2003; 361:827- 33.
Iwamoto J, Takeda T, Ichimura S. combined treatment with vitamin K2 and bisphosphonate in postmenopausal women with osteoporosis. Yonsei Med J 2003; 44:751–756.
Khalil A and Youssef G. Protective effect of vitamin D&K against arterial calcification in overectomized rats. Nat Sci 2013;11(12):239-246.
Cranenburg. The circulating inactive form of Matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vase Res 2008; 45: 427^136.
Parker, BD, Schurgers, LJ, Vermeer, C, et al: The association of uncarboxylated matrix Gla protein with mitral annular calcification differs by diabetes status: The Heart and Soul study. Atherosclerosis 2010:320-325.
Schurgers LJ, Teunissen KJ, Knapen MH, et al, Novel conformation-specific antibodies against matrix gammacarboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005 (25):1629– 1633.
Shroff, Egerton, Bridel, et al: A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008 c; 19: 1239–1246.
Scheiber D, Veulemans V, Horn P, Chatrou M et al: Cardiovascular Calcification in a Murine Model of Extraosseous Calcification. Nutrients 2015, 7, 6991-7011.
Sibal L, Agarwal S, Home P. Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. Diabetes Metab Syndr Obes. 2011; 4: 23–34.
Sathi S, Mahapatra H, Sunder S, Jayaraman R, Sharma N et al: Nontraditional Cardiovascular Biomarkers and Estimation of Cardiovascular Risk in Predialysis Chronic Kidney Disease Patients and Their Correlations With Carotid Intima Media Thickness. Nephrourol Mon. 2014; 6(6): e22112.
Bellasi A, Raggi P. Vascular imaging in chronic kidney disease. Curr Opin Nephrol Hypertens 2012; 21: 382–388.
Caluwé R, Pyfferoen L, Boeck K, and De Vriese A. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clinical Kidney Journal, 2016; 9: (2) 273–279.
Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, et al: Effect of vitamin K2 on progression of atherosclerosis and vascular calcification in non-dialyzed patients with chronic kidney disease stages 3–5. Pol Arch Med Wewn. 2015; 125: 631-640.
Gast GC, de Roos NM, Sluijs I, et al: A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis.2009; 19: 504-510.
Kona V, Yangb H, and Fazio S: Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. Arch Med Res. 2015 July; 46(5): 379–391.
Kawashima H, Nakajima Y, Matubara Y, Nakanowatari J et al. Effects of vitamin K2 (menatetrenone) on atherosclerosis and blood coagulation in hypercholesterolemic rabbits. Jpn J Pharmacol. 1997; 75:135–143.
Nagasawa Y, Fujii M, Kajimoto Y, Imai E, Hori M: Vitamin K2 and serum cholesterol in patients on continuous ambulatory peritoneal dialysis. Lancet. 1998; 351:724.
Delanaye P, Krzesinski JM, Warling X, Moonen M et al: Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrology 2014, 15:145.
Leonard O, Spaak J, and Goldsmith D: Regression of vascular calcification in chronic kidney disease – feasible or fantasy? A review of the clinical evidence. Br J Clin Pharmacol. 2013 Oct; 76(4): 560–572.
This work is licensed under a Creative Commons Attribution 4.0 International License.